New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
08:41 EDTROVIRovi, TP Vision enter multi-year licensing agreement
Rovi announced that it has entered into a multi-year patent license agreement with TP Vision. The licensing terms grant TP Vision use of Roviís discovery patent portfolio for its Philips-branded TV models and related second-screen companion applications and services across multiple international regions.
News For ROVI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:28 EDTROVIRovi price target lowered to $20 form $31 at Brean Capital
Subscribe for More Information
05:59 EDTROVIRovi price target lowered to $26 from $29 at Piper Jaffray
Subscribe for More Information
05:44 EDTROVIRovi price target lowered to $23 from $27 at JPMorgan
JPMorgan analyst Sterling Auty lowered his price target for Rovi (ROVI) to $23 saying the company's Q2 results and guidance were worse than expected. The Netflix (NFLX) litigation outcome has led to slower sales cycles, Auty tells investors in a research note. He sees an uncertain growth outlook going forward and keeps a Neutral rating on Rovi.
July 30, 2015
16:22 EDTROVIRovi to continue pursuing Netflix litigation
Rovi (ROVI) said in its earnings release, "While we are disappointed with the Netflix ruling, we continue to believe in our broader IP licensing business. Our second half focus is on achieving our sales and profit objectives, continuing our big-four renewal negotiations, securing meaningful design wins for our products and continuing to pursue our Netflix litigation."
16:21 EDTROVIRovi says shares undervalued, to buy back $50M in Q3
Rovi said it believes its stock is currently undervalued, and the company intends to repurchase an additional $50M of the companyís shares in Q3, under the existing stock repurchase authorization.
16:20 EDTROVIRovi sees 2015 EPS $1.35-$1.60, consensus $1.70
Sees 2015 revenue $500M-$530M, consensus $546.6M. The company said, "The low-end of this range assumes no new or one-time revenues are recognized in the second-half of 2015, which the Company considers unlikely. The midpoint of this range assumes approximately the same level of new or one-time revenues in the second half of the year as the Company achieved in the first half of 2015."
16:19 EDTROVIRovi reports Q2 EPS 38c, consensus 38c
Subscribe for More Information
July 29, 2015
08:04 EDTROVIRovi extends product, entertainment discovery patent license agreement to Funai
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use